 Connection
David Becton to Humans
This is a "connection" page, showing publications David Becton has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.133 |
|
|
|
-
Stine KC, Becton DL. Bleeding disorders: when is normal bleeding not normal? J Ark Med Soc. 2009 Aug; 106(2):40-2.
Score: 0.014
-
Stine KC, Shrum D, Becton DL. Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors. J Pediatr Hematol Oncol. 2007 Apr; 29(4):216-21.
Score: 0.012
-
Stine KC, Saylors RL, Saccente CS, Becton DL. Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy. Clin Appl Thromb Hemost. 2007 Apr; 13(2):161-5.
Score: 0.012
-
Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood. 2006 Feb 15; 107(4):1315-24.
Score: 0.011
-
Becton DL. Childhood luekemia--success and challenges. J Ark Med Soc. 2005 Sep; 102(3):79-80.
Score: 0.011
-
Stine KC, Saylors RL, Saccente S, McClain KL, Becton DL. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004 Jul; 43(1):81-4.
Score: 0.010
-
Stine KC, Saylors RL, Saccente S, Becton DL. Long-term survival in osteosarcoma patients following retinoblastoma using doxorubicin, cisplatin, and methotrexate. Med Pediatr Oncol. 2003 Jul; 41(1):77-8.
Score: 0.009
-
Mack JM, Pierce CD, Richter GT, Spray BJ, Nicholas R, Lewis PS, Becton D, Crary SE. Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography. Pediatr Blood Cancer. 2021 02; 68(2):e28824.
Score: 0.008
-
Mack JM, Richter GT, Becton D, Salem O, Hill SEM, Crary SE. Short-term side effects and patient-reported outcomes of bleomycin sclerotherapy in vascular malformations. Pediatr Blood Cancer. 2018 06; 65(6):e27008.
Score: 0.006
-
Stine KC, Wahl EC, Liu L, Skinner RA, VanderSchilden J, Bunn RC, Montgomery CO, Aronson J, Becton DL, Nicholas RW, Swearingen CJ, Suva LJ, Lumpkin CK. Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity. J Orthop Res. 2016 10; 34(10):1716-1724.
Score: 0.006
-
Mian A, Becton D, Saylors R, James L, Tang X, Bhutta A, Prodhan P. Biomarkers for risk stratification of febrile neutropenia among children with malignancy: a pilot study. Pediatr Blood Cancer. 2012 Aug; 59(2):238-45.
Score: 0.004
-
Cash T, Becton D, Mian A. Cardiac myeloid sarcoma: a case report and review of literature. J Pediatr Hematol Oncol. 2011 Oct; 33(7):e330-2.
Score: 0.004
-
Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, Lange BJ, Hurwitz C, Arceci RJ, Radich JP, Bernstein ID, Heinrich MC, Meshinchi S. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010 Mar 25; 115(12):2372-9.
Score: 0.004
-
Mian A, Becton D, Blackall DP, James SH, Berman DM, Owusu JA, Turner C, Givner LB, Shetty AK. Index of suspicion. Pediatr Rev. 2009 Apr; 30(4):139-45.
Score: 0.003
-
Horan JT, Alonzo TA, Lyman GH, Gerbing RB, Lange BJ, Ravindranath Y, Becton D, Smith FO, Woods WG. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol. 2008 Dec 10; 26(35):5797-801.
Score: 0.003
-
O'Brien MM, Taub JW, Chang MN, Massey GV, Stine KC, Raimondi SC, Becton D, Ravindranath Y, Dahl GV. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. J Clin Oncol. 2008 Jan 20; 26(3):414-20.
Score: 0.003
-
Savasan S, Buck S, Raimondi SC, Becton DL, Weinstein H, Chang M, Ravindranath Y. CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome. Leuk Lymphoma. 2006 Oct; 47(10):2076-83.
Score: 0.003
-
Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, Stout ML, Buck SA, Massey G, Becton DL, Weinstein HJ, Ravindranath Y, Matherly LH, Taub JW. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood. 2006 Feb 15; 107(4):1570-81.
Score: 0.003
-
Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, Dahl GV. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood. 2004 Nov 01; 104(9):2646-54.
Score: 0.002
-
Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Baruchel S, Pratt C. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. J Clin Oncol. 2002 Mar 15; 20(6):1617-24.
Score: 0.002
-
Parham DM, Ready R, Stine K, Quiggins C, Becton D, North P. Comparison of manual and automated leukocyte counts for determination of the absolute neutrophil count: application to a pediatric oncology clinic. Med Pediatr Oncol. 2002 Mar; 38(3):183-6.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|